VanEck Biotech ETF (NASDAQ:BBH) Shares Sold by Tyler Stone Wealth Management

Tyler Stone Wealth Management decreased its holdings in shares of VanEck Biotech ETF (NASDAQ:BBH) by 5.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,399 shares of the company’s stock after selling 73 shares during the quarter. Tyler Stone Wealth Management owned about 0.06% of VanEck Biotech ETF worth $220,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in BBH. Farther Finance Advisors LLC purchased a new position in VanEck Biotech ETF in the fourth quarter valued at about $32,000. Truvestments Capital LLC acquired a new stake in shares of VanEck Biotech ETF in the third quarter valued at about $44,000. FSA Wealth Management LLC purchased a new stake in shares of VanEck Biotech ETF during the 3rd quarter valued at about $54,000. SBI Securities Co. Ltd. acquired a new position in VanEck Biotech ETF during the 4th quarter worth approximately $81,000. Finally, Wilmington Savings Fund Society FSB purchased a new position in VanEck Biotech ETF in the 3rd quarter worth approximately $166,000. 32.05% of the stock is owned by hedge funds and other institutional investors.

VanEck Biotech ETF Stock Down 1.1 %

Shares of NASDAQ:BBH opened at $158.92 on Thursday. The company has a market capitalization of $387.76 million, a price-to-earnings ratio of 33.67 and a beta of 0.85. The company has a 50 day moving average of $162.99 and a two-hundred day moving average of $166.79. VanEck Biotech ETF has a 52-week low of $151.35 and a 52-week high of $183.64.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.